ArticleCureus2025
Palliative Care Approach in a Case of Severe Nonketotic Hyperglycinemia With Long Survival: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonketotic hyperglycinemia (NKH) is a rare autosomal recessive metabolic disorder characterized by defective glycine cleavage, resulting in glycine accumulation, particularly in the central nervous system. The severe neonatal form typically presents with early-onset encephalopathy, refractory epilepsy, and poor neurodevelopment, often leading to early mortality. We report a male patient with genetically confirmed severe NKH who is currently alive at seven years of age - one of the longest reported survivals for this form. He presented within the first day of life with hypotonia, myoclonic seizures, and coma. Diagnosis was supported by markedly elevated glycine levels in plasma, urine, and cerebrospinal fluid (CSF), with a CSF/plasma glycine ratio of 0.19, as well as characteristic MRI findings. Despite early institution of glycine-lowering agents and antiepileptic therapy, he developed refractory epilepsy and profound neurodevelopmental delay. Comprehensive and continuous multidisciplinary care, including pediatric palliative care, was established early and coordinated across care settings. Although there is no curative therapy for severe NKH, this case illustrates that early and sustained multidisciplinary palliative care can significantly enhance the quality of life and potentially extend survival in affected patients. While developmental outcomes remained poor, the integrated care model minimized hospitalizations, stabilized clinical status, and provided essential family support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.